H.C. Wainwright analyst Robert Burns reiterated a Buy rating on Immunomedics (NASDAQ:IMMU) on Tuesday, setting a price target of $56, which is approximately 49.17% above the present share price of $37.54.
Burns expects Immunomedics to post earnings per share (EPS) of -$0.44 for the third quarter of 2020.
The current consensus among 9 TipRanks analysts is for a Strong Buy rating of shares in Immunomedics, with an average price target of $43.
The analysts price targets range from a high of $56 to a low of $31.
In its latest earnings report, released on 03/31/2020, the company reported a quarterly revenue of $0 and a net profit of -$81.97 million. The company's market cap is $9.38 billion.
According to TipRanks.com, H.C. Wainwright analyst Robert Burns is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 29.7% and a 78.57% success rate.
Immunomedics, Inc. researching, developing, manufacturing, and marketing biopharmaceutical products. It focuses on monoclonal antibody-based products for the targeted treatment of cancer. The company was founded by David M. Goldenberg in July 1982 and is headquartered in Morris Plains, NJ.